Development of a humanised antibody to MIC-1/GDF15 for therapy of anorexia/cachexia of cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1017594

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Severe starvation and weight loss (cachexia) is a complication that affects about one quarter of cancer patients. In many this is due to the cancer producing a powerfula appetite suppressive protein called MIC-1/GDF15. This weight loss can be prevented by blocking the protein with an antibody drug. We have already shown that we can treat mice in this way by using a mouse antibody. We now aim to engineer these antibodies by making them more human-like. This will allow us to treat weight loss in human cancer patients.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: Development Grants

Funding Amount: $587,349.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Molecular Engineering of Nucleic Acids and Proteins

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody cancer therapy | antibody engineering | cachexia | cancer | macrophage inhibitory cytokine 1 (MIC-1) | monoclonal antibody | pharmaceutical treatment

Related Links